Table 1

Clinical characteristics of LDCT-screened subjects referred for ILD evaluation

CharacteristicsLDCT-screened subjects referred to tertiary ILD centre (n=43)
Age, year 68.8 (SD:4.8)
Female sex, n (%)16 (37.2)
Smoking status, n (%)
Former35 (81.4)
Current8 (18.6)
Pack years, n 40.4 (SD:22.6)
Symptoms, n (%)
None20 (46.5)
Dyspnoea10 (23.3)
Cough5 (11.6)
Cough and dyspnoea8 (18.6)
Inhaled exposures, n (%)
None19 (44.2)
Birds5 (11.6)
Mould3 (7.0)
Asbestos11 (25.6)
>1 exposure2 (4.6)
Not available3 (7.0)
Gastro-oesophageal reflux disease, n (%)13 (30.2)
Chest auscultation findings*, n (%)
Normal4 of 21 (19.0)
Crackles17 of 21 (80.9)
Autoimmune screen, n (%)
Positive4 (9.3)
Not available9 (20.9)
Baseline lung function
FEV1, % pred92.2 (SD:17.9)
FVC, % pred89.5 (SD:14.2)
FEV1/FVC73.4 (SD:7.1)
DLco, % pred63.6 (SD:14.0)
Kco, % pred80.6 (SD:12.7)
Diagnostic procedures, n (%)
BAL Transbronchial lung cryobiopsy8 (18.6) 1 (2.3)
  • Data presented as mean (SD:xx) where indicated. *Physical examination was performed in 21/43 (48.8%) subjects due to restrictions imposed by the COVID-19 pandemic.

  • BAL, bronchoalveolar lavage; DLco, lung diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ILD, interstitial lung disease; Kco, carbon monoxide transfer coefficient; LDCT, low-dose CT.